Headlines about BioScrip (NASDAQ:BIOS) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioScrip earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.7659299155274 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

BIOS has been the subject of a number of research reports. ValuEngine raised shares of BioScrip from a “strong sell” rating to a “sell” rating in a report on Thursday, November 9th. BidaskClub raised shares of BioScrip from a “hold” rating to a “buy” rating in a report on Thursday. SunTrust Banks reaffirmed a “buy” rating and set a $3.00 target price on shares of BioScrip in a report on Friday, November 3rd. Finally, Zacks Investment Research lowered shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $3.63.

Shares of BioScrip (BIOS) opened at $3.00 on Monday. BioScrip has a 1-year low of $1.21 and a 1-year high of $3.39. The stock has a market cap of $382.55, a price-to-earnings ratio of -4.41 and a beta of 0.27. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11.

BioScrip (NASDAQ:BIOS) last released its earnings results on Thursday, November 2nd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). The firm had revenue of $198.70 million for the quarter, compared to analyst estimates of $202.91 million. During the same period last year, the firm earned ($0.12) earnings per share. The firm’s quarterly revenue was down 11.5% on a year-over-year basis. equities research analysts forecast that BioScrip will post -0.63 EPS for the current fiscal year.

In other news, CEO Daniel E. Greenleaf acquired 15,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The stock was purchased at an average price of $2.03 per share, with a total value of $30,450.00. Following the completion of the acquisition, the chief executive officer now owns 31,000 shares of the company’s stock, valued at approximately $62,930. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact BioScrip (BIOS) Share Price” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-bioscrip-bios-share-price/1798391.html.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Insider Buying and Selling by Quarter for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with Analyst Ratings Network's FREE daily email newsletter.